MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Начало・Списък с акции・Palatin Technologies Inc

Palatin Technologies Inc

Затворен

0.51 -1.92

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.49

Максимум

0.52

Ключови измерители
By Trading Economics
Служители	30

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+1272.55% upside

Дивиденти
By Dow Jones
Следващи печалби	14.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	15M
Предишно отваряне	2.43
Предишно затваряне	0.51

Palatin Technologies Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.04.2025 г., 22:38 ч. UTC

Горещи акции

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

7.04.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy: Stonepeak's Total Contribution Lower Than Nominal Equity Interest Give Accelerated Spend

6.04.2025 г., 23:58 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy: Deal 'a Material Step' Toward Readiness for Final Investment Decision

6.04.2025 г., 23:58 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy: Deal 'Significantly Reduces' Company's Capex Profile

6.04.2025 г., 23:57 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy: Stonepeak to Contribute 75% of Project Capex in Both 2025, 2026

6.04.2025 г., 23:57 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy: Stonepeak to Provide $5.7 Billion Towards Expected Project Capex

6.04.2025 г., 23:57 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.04.2025 г., 23:57 ч. UTC

Пазарно говорене

Nervous Start For AUD/USD; Watch on CNY Fix -- Market Talk

6.04.2025 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy: Signs Deal With Stonepeak for Sale of 40% Interest in Louisiana LNG Infrastructure

6.04.2025 г., 23:52 ч. UTC

Пазарно говорене

Gold Slips; Likely Unwinding of Long Positions to Raise Cash -- Market Talk

6.04.2025 г., 23:39 ч. UTC

Пазарно говорене

Oil Futures Slide on Fears of Weakening Global Demand -- Market Talk

6.04.2025 г., 23:39 ч. UTC

Пазарно говорене

Nikkei May Fall as U.S. Tariffs Weigh on Global Econ Outlook -- Market Talk

6.04.2025 г., 23:39 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

6.04.2025 г., 23:38 ч. UTC

Придобивния, сливания и поглъщания

Challenger: Reinsurance Relationship With MS Primary Will Continue

6.04.2025 г., 23:38 ч. UTC

Придобивния, сливания и поглъщания

Challenger: Acquisition at 53% Premium to Most Recent Share Price

6.04.2025 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Challenger: Acquisition Subject to Regulatory Approvals

6.04.2025 г., 23:36 ч. UTC

Придобивния, сливания и поглъщания

Challenger: Dai-ichi Life Acquiring Stake From MS&AD Insurance

6.04.2025 г., 23:36 ч. UTC

Придобивния, сливания и поглъщания

Challenger: Dai-ichi Life Paying About A$8.46/Share

6.04.2025 г., 23:35 ч. UTC

Придобивния, сливания и поглъщания

Challenger: Dai-ichi Life Agrees to Acquire 15.1% Interest

6.04.2025 г., 21:58 ч. UTC

Топ новини

Bitcoin Is Falling Amid Global Market Swoon -- Barrons.com

6.04.2025 г., 13:00 ч. UTC

Топ новини

Trump Promised to Lower Energy Prices -- But It Wasn't Supposed to Be Like This -- WSJ

5.04.2025 г., 15:45 ч. UTC

Топ новини

Republicans Advance Trump's Tax Cuts After Late-Night Session -- Update

5.04.2025 г., 15:00 ч. UTC

Топ новини

U.S.-Stock Funds Have a Quarter to Forget -- Journal Report

5.04.2025 г., 15:00 ч. UTC

Топ новини

The Complicated Relationship Between Consumer Sentiment and Stocks -- Journal Report

5.04.2025 г., 14:38 ч. UTC

Топ новини

Trump's Trade Broadside Puts Chinese Economy Under Heavy Pressure -- WSJ

5.04.2025 г., 06:44 ч. UTC

Топ новини

Republicans Advance Trump's Tax Cuts After Late-Night Session -- WSJ

5.04.2025 г., 01:00 ч. UTC

Придобивния, сливания и поглъщания

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ

5.04.2025 г., 01:00 ч. UTC

Придобивния, сливания и поглъщания

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ -2-

4.04.2025 г., 21:53 ч. UTC

Пазарно говорене

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4.04.2025 г., 21:44 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

Сравнение с други в отрасъла

Ценова промяна

Palatin Technologies Inc Прогноза

Ценова цел

By TipRanks

1272.55% нагоре

12-месечна прогноза

Среден 7 USD 1272.55%

Висок 7 USD

Нисък 7 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Palatin Technologies Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Palatin Technologies Inc през последните 3 месеца.

Финанси

Относно Palatin Technologies Inc

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.